Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: A survival-adjusted cumulative incidence analysis.
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- July 15, 2004
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Journal of Clinical Oncology Journal